COX-2 Inhibition mediated anti-angiogenic activatable prodrug potentiates cancer therapy in preclinical models
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Kim, Hyeong Seok | - |
dc.contributor.author | Sharma, Amit | - |
dc.contributor.author | Ren, Wen Xiu | - |
dc.contributor.author | Han, Jiyou | - |
dc.contributor.author | Kim, Jong Seung | - |
dc.date.accessioned | 2021-09-02T02:31:41Z | - |
dc.date.available | 2021-09-02T02:31:41Z | - |
dc.date.created | 2021-06-19 | - |
dc.date.issued | 2018-12 | - |
dc.identifier.issn | 0142-9612 | - |
dc.identifier.uri | https://scholar.korea.ac.kr/handle/2021.sw.korea/71376 | - |
dc.description.abstract | Anti-angiogenesis, i.e., blocking the angiogenic pathway, has been considered as an important component in current cancer therapeutic modalities. However, the associated benefits have proven to be modest as tumor angiogenesis and regrowth persist, probably due to other ill-defined complex angiogenic mechanisms. Herein, we developed an indomethacin (IMC) incorporating system to mediate hypoxia responsive prodrug (TA) and diagnostic agent (DA) in cancer theranostic applications. Cyclooxygenase 2 (COX-2) elevated expression in several cancer types is closely associated with severe tumor supporting vascularization factors. Our strategy utilizing COX-2 inhibition augmented the anti-angiogenetic induced hypoxia responsive prodrug activation well. Both in vitro and in vivo results proved that DA and TA exhibited specificity towards COX-2 positive (+ ve) HeLa and A549 cancer cell lines and activation under hypoxic conditions. Compared with controls (R1, and anticancer drug SN-38), TA displayed prolonged tumor retention and enhanced therapeutic efficacy in xenograft mouse models at a reduced dosage. Our results significantly highlighted the importance of COX-2 blockade mediated anti-angiogenesis in complementing the hypoxia-responsive drug delivery systems (DDSs) and could to beneficial for the rapid development of more efficacious antitumor therapeutics. | - |
dc.language | English | - |
dc.language.iso | en | - |
dc.publisher | ELSEVIER SCI LTD | - |
dc.subject | FLUORESCENT IMAGING AGENTS | - |
dc.subject | TUMOR ANGIOGENESIS | - |
dc.subject | CISPLATIN RESISTANCE | - |
dc.subject | HYPOXIA | - |
dc.subject | CYCLOOXYGENASE-2 | - |
dc.subject | CELLS | - |
dc.subject | EXPRESSION | - |
dc.subject | INDOMETHACIN | - |
dc.subject | INFLAMMATION | - |
dc.subject | TARGET | - |
dc.title | COX-2 Inhibition mediated anti-angiogenic activatable prodrug potentiates cancer therapy in preclinical models | - |
dc.type | Article | - |
dc.contributor.affiliatedAuthor | Kim, Jong Seung | - |
dc.identifier.doi | 10.1016/j.biomaterials.2018.09.006 | - |
dc.identifier.scopusid | 2-s2.0-85054676252 | - |
dc.identifier.wosid | 000448494500006 | - |
dc.identifier.bibliographicCitation | BIOMATERIALS, v.185, pp.63 - 72 | - |
dc.relation.isPartOf | BIOMATERIALS | - |
dc.citation.title | BIOMATERIALS | - |
dc.citation.volume | 185 | - |
dc.citation.startPage | 63 | - |
dc.citation.endPage | 72 | - |
dc.type.rims | ART | - |
dc.type.docType | Article | - |
dc.description.journalClass | 1 | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
dc.relation.journalResearchArea | Engineering | - |
dc.relation.journalResearchArea | Materials Science | - |
dc.relation.journalWebOfScienceCategory | Engineering, Biomedical | - |
dc.relation.journalWebOfScienceCategory | Materials Science, Biomaterials | - |
dc.subject.keywordPlus | FLUORESCENT IMAGING AGENTS | - |
dc.subject.keywordPlus | TUMOR ANGIOGENESIS | - |
dc.subject.keywordPlus | CISPLATIN RESISTANCE | - |
dc.subject.keywordPlus | HYPOXIA | - |
dc.subject.keywordPlus | CYCLOOXYGENASE-2 | - |
dc.subject.keywordPlus | CELLS | - |
dc.subject.keywordPlus | EXPRESSION | - |
dc.subject.keywordPlus | INDOMETHACIN | - |
dc.subject.keywordPlus | INFLAMMATION | - |
dc.subject.keywordPlus | TARGET | - |
dc.subject.keywordAuthor | Anti-angiogenesis | - |
dc.subject.keywordAuthor | COX-2 | - |
dc.subject.keywordAuthor | Hypoxia | - |
dc.subject.keywordAuthor | Indomethacin | - |
dc.subject.keywordAuthor | Cancer therapy | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
(02841) 서울특별시 성북구 안암로 14502-3290-1114
COPYRIGHT © 2021 Korea University. All Rights Reserved.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.